These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31162273)

  • 1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Pich J
    Int J Evid Based Healthc; 2019 Sep; 17(3):187-188. PubMed ID: 31162273
    [No Abstract]   [Full Text] [Related]  

  • 2. Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada.
    Gupta AK; Daigle D; Lyons DC
    J Cutan Med Surg; 2014 Nov; 18(6):371-8. PubMed ID: 25348757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the role of topical calcipotriol in the treatment of mild to moderate chronic plaque psoriasis?
    Popescu CM; Popescu R
    Arch Dermatol; 2000 Dec; 136(12):1547-9. PubMed ID: 11115169
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab for plaque psoriasis.
    Ordenes-Cavieres G; Andino-Navarrete R
    Medwave; 2018 Nov; 18(7):e7364. PubMed ID: 30507896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
    Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100.
    Manalo IF; Gilbert KE; Wu JJ
    J Drugs Dermatol; 2015 Oct; 14(10):1086-8. PubMed ID: 26461817
    [No Abstract]   [Full Text] [Related]  

  • 10. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab drug survival in chronic plaque psoriasis: follow-up of the product familiarisation program.
    Berry W; Daniel B; Nguyen R; Baker C; Foley P
    Australas J Dermatol; 2020 Nov; 61(4):e472-e474. PubMed ID: 32314344
    [No Abstract]   [Full Text] [Related]  

  • 13. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
    Bigby M
    Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
    [No Abstract]   [Full Text] [Related]  

  • 15. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The biological treatments for moderate to severe plaque psoriasis].
    Thielen AM; Marazza G
    Rev Med Suisse; 2008 Apr; 4(155):1089-90, 1092-4. PubMed ID: 18610721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 18. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
    Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
    J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Rosumeck S; Thomaschewski G; Sporbeck B; Haufe E; Nast A
    Br J Dermatol; 2014 Feb; 170(2):274-303. PubMed ID: 24131260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapies for psoriasis: an evidence-based update.
    Sandoval LF; Pierce A; Feldman SR
    Am J Clin Dermatol; 2014 Jul; 15(3):165-80. PubMed ID: 24496885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.